Open AccessCationic amphiphilic drugs as potential anticancer therapy for bladder cancer
Author(s) -
Horst Geertje,
Merbel Arjanneke F.,
Ruigrok Eline,
Mark Maaike H.,
Ploeg Emily,
Appelman Laura,
Tvingsholm Siri,
Jäätelä Marja,
Uhm Janneke,
Kruithofde Julio Marianna,
Thalmann George N.,
Pelger Rob C. M.,
Bangma Chris H.,
Boormans Joost L.,
Pluijm Gabri,
Zwarthoff Ellen C.
Publication year - 2020
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12793
Subject(s) - medicine , drug repositioning , bladder cancer , in vivo , ex vivo , drug , pharmacology , dosing , cancer research , cancer , clinical trial , oncology , biology , microbiology and biotechnology
Repurposing FDA‐approved, antipsychotic cationic amphiphilic drugs like penfluridol dose‐dependently decreased viability of human bladder cancer cells, significantly reduced tumor progression and metastasis in an orthotopic human bladder cancer xenograft model, and induced significant antitumor responses in patient‐derived, ex vivo cultured bladder cancer tissue. Clinically approved penfluridol is a promising antineoplastic agent for bladder cancer patients for which effective therapy is currently lacking.